Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

Rhea-AI Summary

Tarsus (NASDAQ: TARS) will report fourth quarter and full year 2025 financial results on Monday, February 23, 2026. A live webcast will begin at 1:30 p.m. PT / 4:30 p.m. ET, with a recorded replay available on the company website and archived for about 90 days.

The company will provide a corporate update during the call; investors can access the live webcast via the company’s investor site.

News Market Reaction – TARS

+3.29%

3 alerts

+3.29% News Effect

+$86M Valuation Impact

$2.71B Market Cap

0.3x Rel. Volume

On the day this news was published, TARS gained 3.29%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $86M to the company's valuation, bringing the market cap to $2.71B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings call time (PT): 1:30 p.m. PT Earnings call time (ET): 4:30 p.m. ET Earnings date: February 23, 2026 +1 more

4 metrics

Earnings call time (PT) 1:30 p.m. PT Scheduled Q4 and full-year 2025 webcast on February 23, 2026

Earnings call time (ET) 4:30 p.m. ET Scheduled Q4 and full-year 2025 webcast on February 23, 2026

Earnings date February 23, 2026 Fourth quarter and full year 2025 financial results

Webcast archive duration approximately 90 days Recording available on company website after the call

Market Reality Check

Price: $66.61 Vol: Volume 491,768 is slightl...

normal vol

$66.61 Last Close

Volume Volume 491,768 is slightly below the 20-day average of 556,942 ahead of the scheduled earnings call. normal

Technical Shares at $62.78 are trading above the 200-day MA of $59.25 and about 26.36% below the 52-week high of $85.25.

Peers on Argus

TARS is down 3.91% while key biotech peers like ARQT (+2.94%), IRON (+17.78%), O...

TARS is down 3.91% while key biotech peers like ARQT (+2.94%), IRON (+17.78%), OCUL (+9.05%), AGIO (+0.07%) and TVTX (+3.31%) are positive, indicating stock-specific weakness rather than a sector-wide move.

Historical Context

5 past events · Latest: Nov 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 24	Conference participation	Neutral	-3.9%	Announced fireside chat at BTIG Ophthalmology Day with webcast details.
Nov 05	Conference participation	Neutral	-0.2%	Management participation in Guggenheim healthcare conference with webcast access.
Nov 04	Earnings release	Positive	-4.6%	Q3 2025 results with strong XDEMVY sales growth and narrowed net loss.
Oct 28	Earnings date set	Neutral	-0.1%	Scheduled Q3 2025 earnings webcast and outlined replay availability.
Aug 27	Conference participation	Neutral	+0.6%	Planned presentations at two September 2025 investor healthcare conferences.

Pattern Detected

Neutral scheduling and conference updates have typically seen muted, small price moves, while fundamentally positive earnings results have coincided with short-term share price declines.

Recent Company History

Over the last six months, Tarsus has frequently issued conference and event notices, as well as earnings updates. Neutral items such as investor conference participation and prior earnings date announcements around Aug 27, Oct 28, and Nov 5, 2025 saw minimal price impact. By contrast, the Nov 4, 2025 Q3 2025 results release, which highlighted strong XDEMVY growth and improving losses, was followed by a 4.62% decline. Today’s earnings date notice fits the pattern of largely informational scheduling updates.

Market Pulse Summary

This announcement sets expectations for Tarsus’ fourth quarter and full year 2025 update on February...

Analysis

This announcement sets expectations for Tarsus’ fourth quarter and full year 2025 update on February 23, 2026, when management plans to provide financial results and a corporate update. Past Q3 2025 reporting highlighted rapid XDEMVY growth alongside continued investment and net losses. Investors may focus on revenue trends, cash position, and development milestones relative to those prior figures, using the webcast and 90-day archive as key sources for detailed information.

AI-generated analysis. Not financial advice.

IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update.

Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, all of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

When will Tarsus (TARS) report Q4 and full year 2025 results?

Tarsus will report on Monday, February 23, 2026 at 1:30 p.m. PT / 4:30 p.m. ET. According to Tarsus, the company will host a live webcast that day to present fourth quarter and full year 2025 financial results and a corporate update.

How can investors access the Tarsus (TARS) earnings webcast on February 23, 2026?

Investors can join the live webcast via the company’s investor website at the scheduled time. According to Tarsus, a recorded version will be posted shortly after the call and archived on the website for approximately 90 days for later viewing.

Will Tarsus (TARS) provide a replay of the February 23, 2026 webcast?

Yes. A recorded version will be available shortly after the webcast and archived for about 90 days. According to Tarsus, the replay will be posted on the company website so investors can review the corporate update and financial commentary.

What time is the Tarsus (TARS) investor call for Q4 and full year 2025 results?

The investor call begins at 1:30 p.m. PT / 4:30 p.m. ET on February 23, 2026. According to Tarsus, the live webcast will include financial results and a corporate update and will be accessible through the company’s investor relations page.

Will Tarsus (TARS) discuss a corporate update during the February 23, 2026 webcast?

Yes. The company will provide a corporate update alongside financial results during the webcast. According to Tarsus, the presentation will cover fourth quarter and full year 2025 results plus a corporate update for investors and analysts.